The drugmaker’s announcement comes as concerns about COVID-19 vaccine and treatment access abound. The decision allows other drugmakers and governments to develop COVID-19 medical products based on Moderna’s technology.
“We feel a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible,” the announcement reads.
However, some consumer groups have expressed they do not feel the drugmaker’s motivations are so pure. These groups presume the decision was made to eschew expensive patent litigation, as Moderna executives disclosed they were unsure if their company was the first to discover the inventions claimed in their patents during a securities filing in August, according to STAT.
More articles on pharmacy:
Walgreens pharmacies to offer expanded clinical services in Chicago
Health officials scramble to get $200 Medicare drug cards out by Election Day
Eli Lilly, Gates Foundation to supply COVID-19 antibody drug to low-income countries
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
